Bibliography
- Chrischilles E, Gilden D, Kubisiak J, Delivery of ipratropium and albuterol combination therapy for chronic obstructive pulmonary disease: effectiveness of a two-in-one inhaler versus separate inhalers. Am J Manag Care 2002;8(10):902-11
- Friedman M, Serby CW, Menjoge SS, Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest 1999;115(3):635-41
- Ray NC, Alcaraz L. Muscarinic antagonist-beta-adrenergic agonist dual pharmacology molecules as bronchodilators: a patent review. Expert Opin Ther Patents 2009;19(1):1-12
- Steinfeld T, Hughes AD, Klein U, THRX-198321 is a bifunctional muscarinic receptor antagonist and beta2-adrenoceptor agonist (MABA) that binds in a bimodal and multivalent manner. Mol Pharmacol 2011;79(3):389-99
- McNamara A, Steinfeld T, Pulido-Rios MT, Preclinical efficacy of THRX-200495, a dual pharmacology muscarinic receptor antagonist and beta(2)-adrenoceptor agonist (MABA). Pulm Pharmacol Ther 2012; In press
- Norman P. Dual-acting beta2 agonists/muscarinic antagonists. Expert Opin Ther Patents 2006;16:1327-31
- Glaxo Group Ltd. Process for the preparation of a biphenyl-2-ylcarbamic acid ester. WO2010119064; 2010
- Norris V, Zhu CQ, Ambery C. The pharmacodynamics of GSK961081 in patients with COPD [Abstract]. European Respiratory Society Annual Congress; 2011
- NCT01498081 A Single-dose Study to Investigate the Effects of 3 Different Doses of Inhaled AZD2115 in COPD Patients. Available from: www.clinicaltrials.gov
- Argenta Discovery Ltd, AstraZeneca AB. Nitrogen containing hetrocyclic compounds useful as bifunctional modulators of M3 receptors and beta- 2 receptors. WO2008096129; 2008
- Argenta Discovery Ltd, AstraZeneca AB. Bicyclo [2.2.1]hept-7-ylamine derivatives and their use in the treatment of diseases and conditions in which M3 muscarinic receptor activity and beta-adrenergic activity are implicated. WO2008149110; 2008
- AstraZeneca AB. Pulmagen Therapeutics (Synergy) Ltd, Compounds. WO2009098448; 2009
- AstraZeneca AB. Pulmagen Therapeutics (Synergy) Ltd, Diazaspiro [5.5] undecane derivatives and related compounds as muscarinic-receptor antagonists and beta-adrenoreceptor agonists for the treatment of pulmonary disorders. WO2010067102; 2010
- AstraZeneca AB. Pulmagen Therapeutics (Synergy) Ltd, Spirocyclic amide derivatives. WO2011012896; 2011
- AstraZeneca AB. Pulmagen Therapeutics (Synergy) Ltd, Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity. WO2011048409; 2011
- AstraZeneca AB. Pulmagen Therapeutics (Synergy) Ltd, Compounds. WO2011154678; 2011
- AstraZeneca AB. Pulmagen Therapeutics (Synergy) Ltd, Azole and thiazole derivatives and their use. WO2007017669; 2007
- AstraZeneca AB. Pulmagen Therapeutics (Synergy) Ltd New combinations for the treatment of asthma. WO2011012897; 2011
- AstraZeneca AB. Pulmagen Therapeutics (Synergy) Ltd Compound. WO2012085582; 2012
- AstraZeneca AB. Pulmagen Therapeutics (Synergy) Ltd New Compound. WO2012085583; 2012
- Kaiser C, Dandridge PA, Garvey E, Dopamine receptor agonist activity of some 5-(2-aminoethyl)carbostyril derivatives. J Med Chem 1985;28(12):1803-10
- Prat M, Gavalda A, Fonquerna S, Miralpeix M. Inhaled muscarinic antagonists for respiratory diseases: a review of patents and current developments (2006 – 2010). Expert Opin Ther Patents 2011;21(10):1543-73
- Stocks MJ, Alcaraz L, Bailey A, The discovery of new spirocyclic muscarinic M3 antagonists. Bioorg Med Chem Lett 2010;20(24):7458-61
- AstraZeneca AB. Pulmagen Therapeutics (Synergy) Ltd Compounds. US8148373; 2012